Patient Reported Outcomes from a Randomized Controlled Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica
The poster reports the patient reported outcomes from the SAPHYR study. Patients treated with sarilumab 200mg Q2W + 14-week GC had clinically meaningful and robust improvement in patient reported outcomes compared to patients receiving placebo + 52-week GC.
Author(s):
- Vibeke Strand, Division of Immunology and Rheumatology, Stanford University
- Jennifer Sloane Lazar
- Michael C Nivens
- Jingdong Chao
- Stefano Fiore
- Angeliki Glannelou
- Lita Araujo Araujo
- Jerome Msihid
| Display Label | Action |
|---|